Ligand Pharmaceuticals
LGND
180 hedge funds and large institutions have $1.15B invested in Ligand Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 65 increasing their positions, 63 reducing their positions, and 23 closing their positions.
30% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 23
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
11% more capital invested
Capital invested by funds: $1.04B → $1.15B (+$118M)
3% more funds holding
Funds holding: 174 → 180 (+6)
3% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 63
26% less call options, than puts
Call options by funds: $1.82M | Put options by funds: $2.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FMA
Fiduciary Management Associates
Chicago,
Illinois
|
+$15.3M |
| 2 |
KI
Kalmar Investments
Greenville,
Delaware
|
+$15.1M |
| 3 |
BC
Broadfin Capital
New York
|
+$10.4M |
| 4 |
William Blair & Company
Chicago,
Illinois
|
+$5.72M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$5.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
-$28.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$24.2M |
| 3 |
CM
Castleark Management
Chicago,
Illinois
|
-$15.9M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$13M |
| 5 |
TCP
TAMRO Capital Partners
Alexandria,
Virginia
|
-$7.18M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IPC
201
Independent Portfolio Consultants
Boca Raton,
Florida
| – | -$135K | -4,609 | Closed |
|
|
PA
202
Perceptive Advisors
New York
| – | -$105K | -3,599 | Closed |
|
203
Group One Trading
Chicago,
Illinois
| – | -$12.5K | -385 | Closed |
|
LGND Hedge Fund Activity: Q4 2014 in Review
180 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2014, worth a combined $1.15B — up 11% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new LGND positions and 23 closed out — a net gain of 7 holders — while 65 added to existing stakes and 63 trimmed.
The largest buyer was Fiduciary Management Associates, opening a new position worth an estimated $15.3M. The largest seller was Gotham Asset Management, cutting an estimated $28.6M.
- 180 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2014, up from 174 in Q3 2014.
- Funds reported $1.15B of Ligand Pharmaceuticals stock for Q4 2014, up 11% quarter-over-quarter.
- 30 funds opened new Ligand Pharmaceuticals positions in Q4 2014 and 23 closed out, a net change of +7 holders.
- The largest Ligand Pharmaceuticals buyer in Q4 2014 was Fiduciary Management Associates, an estimated $15.3M added.
- The largest Ligand Pharmaceuticals seller in Q4 2014 was Gotham Asset Management, an estimated $28.6M sold.
Based on aggregated 13F filings for Q4 2014.